MAP2K7 and non-small cell lung carcinoma: Dual MAPK pathway inhibition using dabrafenib (BRAF inhibitor) plus trametinib (MEK inhibitor) achieved a 64% response rate and a median PFS of 10.9 months in BRAF-V600E mutation-positive NSCLC [86]; the data suggest that the combined treatment of BRAF targeted therapy and targeted agent against MEK in patients with BRAF mutation may be a useful therapeutic strategy in this subset of patients.